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Abstract
INTRODUCTION—Comparative transcriptome analyses in Alzheimer’s disease (AD) and other 
neurodegenerative proteinopathies can uncover both shared and distinct disease pathways.
METHOD—We analyzed 940 brain transcriptomes including patients with AD, progressive 
supranuclear palsy (PSP)-a primary tauopathy and controls.
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RESULTS—We identified transcriptional co-expression networks implicated in myelination, 
which were lower in PSP temporal cortex (TCX) compared to AD. Some of these associations 
were retained even after adjustments for brain cell population changes. These TCX myelination 
network structures were preserved in cerebellum (CER) but they were not differentially expressed 
in CER between AD and PSP. Myelination networks were down-regulated in both AD and PSP, 
when compared to control TCX samples.
DISCUSSION—Down-regulation of myelination networks may underlie both PSP and AD 
pathophysiology, but may be more pronounced in PSP. These data also highlight conservation of 
transcriptional networks across brain regions and the influence of cell- type changes on these 
networks.
Keywords
Proteinopathies; Alzheimer’s disease; progressive supranuclear palsy; myelination; co- expression 
networks; transcriptome; temporal cortex; cerebellum
1. Introduction
Many neurodegenerative diseases, including Alzheimer’s disease (AD), are proteinopathies 
with common features including abnormal deposits of endogenous proteins, which 
propagate through the central nervous system (CNS) and culminate in cellular dysfunction 
and death, leading to clinical syndromes of dementia and/or movement disorders 
(reviewed[1]). Despite their commonalities, key differences are thought to exist in the events 
that trigger one proteinopathy vs. another; as well as in the downstream pathophysiologic 
pathways that distinguish these neurodegenerative diseases. Gene expression profiling 
studies may discover genes implicated in neurodegenerative diseases and uncover the 
complex molecular pathways leading to these disorders[2, 3]. With few exceptions[4–8], 
previous studies have investigated differential gene expression (DGE) in relatively small 
cohorts and were limited to comparison of individual gene transcripts rather than systems-
level analysis. Further, most studies assessed one disease group against controls, rather than 
pursuing comparison between different diseases.
We postulate that comparison of brain gene expression levels in different neurodegenerative 
proteinopathies can uncover molecular pathways that are common to as well as those that 
are distinct for these diseases. Discovery of brain transcriptional networks with differential 
expression between different proteinopathies may uncover molecular pathways that may 
differentially influence these conditions. In contrast, networks that have similar expression 
changes in different diseases in comparison to controls may point to common dysregulated 
molecular pathways.
To test this hypothesis, we focused on two distinct proteinopathies, AD[9, 10] and 
progressive supranuclear palsy (PSP)[11, 12]. Although brain tau protein accumulation is a 
neuropathologic hallmark in both, these conditions are distinguished by different 
predominant tau isoform aggregates[13], and the unique presence in AD[9] of senile plaques 
composed predominantly of amyloid β (Aβ). They also have distinct clinical presentations. 
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AD is the most common type of dementia[10], whereas PSP is a relatively rare parkinsonian 
movement disorder[12].
To identify genes and networks that are differentially altered in these conditions, we 
performed DGE and co-expression network analysis[14] in brain transcriptome[15–17] of 
subjects with AD or PSP. To determine whether observed network differences are driven by 
changes in AD vs. PSP or different extent of change in both, we also compared each 
diagnostic group with elderly control samples without any neurodegenerative diagnoses. All 
co-expression modules (CEM) were tested for enrichment of CNS cell-types[18], to identify 
altered networks that may be indicative of selectively vulnerable cell populations. 
Furthermore, to determine the contribution of cell-population changes to our findings[19], 
we performed all network analyses using two models: Comprehensive Model which adjusted 
for levels of 5 CNS cell-specific transcripts and Simple Model which was not thus adjusted. 
Finally, we validated these results by protein analysis in brain tissue.
Our findings reveal conserved brain myelination networks that are altered in both AD and 
PSP, but to a greater extent in the latter. These results have implications for the role of 
myelin metabolism in the pathophysiology of these distinct neurodegenerative 
proteinopathies, and ultimately for identification of novel therapeutic targets and biomarkers. 
Further, our large-scale transcriptome data, which we made available to the research 
community[16], provides information regarding brain region conservation and CNS cell-
enrichment of transcriptional networks, as well as the influence of cell-population changes 
on their expression patterns.
2. Methods
Please also refer to Supplementary Methods for details.
2.1 Subjects and Samples
In a two-stage design, Mayo Clinic brain expression genome-wide association study 
(eGWAS) was used as the Discovery Cohort and Mayo Clinic RNA sequencing (RNAseq) 
samples were used as the Replication Cohort. The Discovery Cohort[15, 16] had Whole 
Genome DASL array-based transcriptome measurements, whereas the Replication 
Cohort[16, 17] had RNAseq data obtained with 101 base-pair (bp), paired-end sequencing 
on Illumina HiSeq2000 instruments, as previously published. The Discovery Cohort had 
whole genome genotypes from the Illumina HumanHap300-Duo Genotyping 
BeadChips[20], and the Replication Cohort from the Illumina Infinium HumanOmni2.5-8 
BeadChip, which were utilized in quality control (QC).
2.2 Analyses
2.2.1 Differential Gene Expression (DGE)—DGE analyses of brain tissue from 
subjects of two diagnostic categories were conducted with multivariable linear regression 
conducted in R. Discovery Cohort DGE analyses utilized normalized gene expression 
measures as dependent variable, diagnosis as independent variable of primary interest and 
included age at death, gender, number of APOE ε4 alleles, plate, RIN, and (RIN-RINmean)2 
as biological and technical covariates. Replication Cohort DGE analyses used conditional 
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quantile normalized (CQN)[21] gene expression measures as dependent variable, diagnosis 
as independent variable of primary interest and included age at death, gender, RIN, brain 
tissue source, and flowcell as biological and technical covariates. We also included cell 
specific gene levels as covariates to account for neuronal loss, gliosis and/or vascular tissue, 
as previously described[22]. We did this correction by including as covariates, expression 
levels of genes (Probe ID; ENCODE ID) that are specific for the main five cell types present 
in the central nervous system (CNS): ENO2 for neurons (ILMN_1765796, 
ENSG00000111674), GFAP for astrocytes (ILMN_1697176, ENSG00000131095), CD68 
for microglia (ILMN_2267914, ENSG00000129226), OLIG2 for oligodendrocytes 
(ILMN_1727567, ENSG00000205927) and CD34 for endothelial cells (ILMN_1732799, 
ENSG00000174059). Significance accounting for multiple testing was assigned using q 
values which are based on false discovery rates (Benjamini-Hochberg FDR)[23].
Unique genes representing probes with a q value<0.05 for the Discovery Cohort temporal 
cortex DGE analyses were assessed for enrichment of pathways and gene ontology (GO) 
biological processes using Metacore (Thompson Reuters)[24, 25].
2.2.2 Weighted Gene Co-Expression Network Analysis (WGCNA)—WGCNA R 
package[14] version 1.41 was used for both cohorts, independently. In all analyses, gene 
expression residuals obtained after multiple linear regression with independent variables, 
were input to WGCNA. Network analyses were run under two different models: 
“Comprehensive Model”, which adjusts for all covariates described in the above section; and 
“Simple Model”, which adjusts for the same covariates except for the five CNS cell-specific 
gene expression levels.
Networks were built using two diagnostic groups to analyze their associations with 
diagnosis. For each pairwise diagnostic group, consensus modules were identified and tested 
for (GO) enrichment in WGCNA. All modules were further annotated for enrichment of 
genes that are primarily expressed in one of the five major cell types that exist in the CNS, 
i.e. neurons, oligodendrocytes, microglia, astrocytes and endothelia, as described in the next 
section.
Eigengene, the first signed principle component, was calculated for each module. For each 
gene, module membership (MM) was calculated as the correlation between the gene and the 
module eigengene. Genes with MM≥0.7 are considered to be “important (hub)” genes for 
the network. To test the association of disease phenotype with network modules, eigengenes 
of consensus modules were correlated with the binary disease phenotype. Unless otherwise 
specified, “correlation” means Pearson correlation. Preservation of different networks were 
assessed using WGCNA “modulePreservation” function with 100 permutations to calculate 
a Zsummary score, which indicates well-preservation if >10.
2.2.3 Cell-enrichment analyses—Gene expression measures from purified cell 
populations, isolated from human brain tissue, were obtained from Zhang et al[18]. We 
analyzed the 21,390 genes that remained after removal of those that had expression changes 
due to technical issues or duplicates. Genes with a mean gene expression level, FPKM > 5 in 
the target cell and a fold change > 4 when compared with each other cell type, were deemed 
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to be enriched for that target cell. All co-expression modules (CEM) were tested for 
enrichment for each of the 5 human brain cell-enriched genes using a one-sided Fisher’s test.
2.3 Protein analysis
We investigated brain protein levels for the key genes from the oligodendroglial networks 
and other genes of interest using Western blot analysis. We assessed human TCX brain 
tissue from 18 controls against either 20 PSP or 20 AD cases, in addition to 2 control 
samples measured for every protein on every gel to control for potential blot-to-blot 
variability. Differential protein analysis was also conducted for key myelin genes from the 
oligodendroglial networks using proteome data obtained from 84 AD and 83 PSP TCX 
samples from the Mayo Clinic RNAseq Replication Cohort. Myelination patterns were 
assessed in a subset of AD, PSP and control TCX samples (4 each) using established 
immunohistochemistry methods[26, 27]. We evaluated immunocytochemical patterns for the 
myelin and oligodendrocyte proteins using rat oligodendrocyte-enriched cultures[28].
3. Results
3.1 Brain Transcriptome Profiling in the Discovery Cohort identifies transcriptional 
changes in neurodegenerative diseases in the temporal cortex
To determine differentially expressed (DE) genes between human brains with AD vs. PSP, 
we utilized whole transcriptome data from our “Mayo eGWAS Discovery Cohort”[15, 16]. 
Expression levels were obtained from TCX, which is typically affected by AD 
neuropathology but spared in PSP; and from the cerebellar cortex (CER), which is relatively 
spared in AD[9], while the superior cerebellar peduncle and the dentate nucleus may be 
affected in PSP[12]. Following QC (Supplementary Figs. 1–3)[15, 29], 359 subjects with 
WG-DASL microarray expression measures from TCX (181 AD, 178 without AD pathology 
i.e. nAD including 97 PSP) and 343 with CER (173 AD, 170 nAD including 96 PSP) were 
retained (Supplementary Table 1). There were 17,902 WG-DASL probes (13,928 unique 
genes) that were expressed in >50% of all TCX samples analyzed and 17,122 such probes 
(13,440 unique genes) for CER samples (Supplementary Table 2).
We performed DGE using the “Comprehensive Model”, which includes adjustment for 
levels of five genes that have cell-specific expression for the main cell types present in the 
central nervous system (CNS)[18], as previously described[22, 30]. The rationale for this 
cell-type adjustment was to account for brain cell population changes that can occur in CNS 
diseases as a result of neuronal loss or gliosis, which can then influence transcriptome 
profiling outcomes[19] (Supplementary Results). Indeed, we identified significantly lower 
ENO2, but higher GFAP, CD68 and CD34 levels in the TCX, but not the CER, of AD 
subjects in comparison to those without AD pathology (Supplementary Figs. 4A–B), 
consistent with known cellular changes that occur in affected brain regions in AD[31, 32].
DGE results for all pairwise diagnostic comparisons are presented in Supplementary Tables 
3–10 and Supplementary Text. There were 3,381 transcripts (3,094 unique genes) with 
significant DE in the TCX AD vs. PSP analysis (Supplementary Table 4). In contrast, there 
were only 6 significant probes in the CER AD vs. PSP DGE analyses (Supplementary Table 
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6). DGE results in the Discovery Cohort suggested strong transcriptional changes in the 
TCX but not CER for all diagnostic comparisons.
Pathway enrichment analysis of the most significant DEGs in the AD vs. PSP TCX analysis 
(3,094 genes, q< 0.05) implicated 66 enriched GO and MetaCore pathways with an 
FDR<0.05, including established pathways such oxidative phosphorylation, where a 
systematic downregulation in AD TCX of genes in this pathway is observed 
(Supplementary_Table.11, Supplementary_Fig.5), replicating prior observations[21, 28]. In 
the smaller AD vs. nTau analysis (572 genes) “Protein folding and maturation_POMC 
processing” was a significant MetaCore pathway, also detected in the AD vs. PSP analysis. 
Assessment of the 745 unique genes differentially expressed in PSP vs. nTau TCX, detected 
3 significant and overlapping GO processes: “axon ensheathment in central nervous 
system”; “central nervous system myelination” and “oligodendrocyte development”.
3.2 Co-expression network analysis in the Discovery Cohort identifies modules that are 
enriched for specific brain cell types
We constructed co-expression networks[14] under both the “Comprehensive” and “Simple 
Models”, where the latter was implemented given the observed correlation of the cell 
markers with one another (Supplementary Fig. 6, Supplementary Text), leading to the 
possibility of over-correction under the Comprehensive Model. All co-expression modules 
(CEM) were annotated for enrichment of cell-type expressed genes, which are primarily 
expressed in one of five human brain cell types[18] (Supplementary Tables 12–16), and 
which are sufficient to differentiate the cell populations from one another (Supplementary 
Figs. 7–8).
Results are provided for the TCX CEM in the Discovery Cohort under the “Comprehensive” 
(Supplementary Tables 17–20) and “Simple” models (Supplementary Tables 21–24) for all 
pairwise diagnostic groups. CEM naming conventions are shown in Supplementary Table 
25. In the AD+PSP cohort, 44 TCX consensus CEM were identified under the 
“Comprehensive Model” of which 12 had significant enrichment for one of the 5 brain-cell 
enriched gene sets (Supplementary Table 18). Using the “Simple Model”, 31 such TCX 
CEM were identified, of which 10 had enrichment for brain cell-enriched genes 
(Supplementary Table 22). The TCX CEM generated under the Comprehensive and Simple 
Models were well preserved (Supplementary Figs. 9–10). Table 1 shows those TCX CEM in 
the AD+PSP Discovery Cohort that had significant brain cell-enrichment under both 
analytic models (Supplementary Figs. 9–11).
We tested whether CEM are preserved between two brain regions i.e. TCX and CER 
(Supplementary Text, Supplementary Tables 26–33). Similar to the TCX modules, CER 
CEM built under the Simple vs. Comprehensive Models were well-preserved 
(Supplementary Figs. 12–14). Further, CER vs. TCX CEM from the Comprehensive Model 
were well-preserved (Supplementary Figs. 15–17).
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3.3 Myelination co-expression modules have replicable neurodegenerative disease 
association in the temporal cortex
We tested the association of network modules with neuropathologic diagnoses. Under the 
Simple Model, there were 17 CEM that had significant DE in the TCX of AD vs. PSP 
subjects in the Discovery Cohort (Supplementary Table 22), of which 7 also had brain cell-
enrichment (Fig. 1A, Table 1). In contrast, under the Comprehensive Model, there were only 
9 TCX CEM with disease association (Supplementary Table 18), of which 4 had brain cell-
enrichment (Fig. 1B, Table 1). None of the CER CEM with brain cell-enrichment had 
significant association with disease (Table 2), despite being well-preserved with the TCX 
modules.
Inspection of the TCX CEM with disease association and cell-enrichment under both 
analytic models revealed that only the modules enriched in oligodendrocyte transcripts, 
implicated in myelination, had strong preservation under the Simple (Fig. 2A–B, 
AD+PSPTCX11.CSsimple, AD+PSPTCX29.CSsimple) and Comprehensive Models (Fig. 2C–D, 
AD+PSPTCX10.CS, AD+PSPTCX40.CS). Hereforth, we refer to these CEM and others with 
oligodendrocyte-transcript enrichment as “myelination modules”. All four myelination 
modules had higher levels of expression in TCX of AD subjects compared to PSP (Table 1, 
Fig. 1A4, 1A9, 1B3, 1B9). This remarkably consistent association of myelination networks 
with disease irrespective of adjustment for five brain cell-type specific expression markers 
suggested that these networks may be differentially regulated in AD vs. PSP for reasons 
other than brain cell population changes. No other TCX brain cell-enriched modules had 
consistent direction of association with disease under both analytic models.
For these reasons, we focused on the myelination modules in the independent “Mayo Clinic 
RNAseq” Replication Cohort[16]. Following QC of this cohort (Supplementary Figs. 18–
21), expression measures were retained for 80 AD and 82 PSP subjects, as well as 76 elderly 
controls. The 13,273 TCX RNAseq transcripts (13,211 unique genes) which overlapped with 
those from the Discovery Cohort were utilized in all downstream analyses. In the co-
expression network AD vs. PSP analyses of the Replication Cohort, one myelination module 
was identified under the Simple Model (Table 3, Fig. 2E, AD+PSPTCX3.CSRSsimple); and 
three such modules under the Comprehensive Model (AD+PSPTCX2.CSRS, 
AD+PSPTCX8.CSRS, AD+PSPTCX26.CSRS).
The Simple Model myelination module (AD+PSPTCX3.CSRSsimple) was highly preserved 
with the corresponding modules from the Discovery Cohort (Supplementary Fig. 22–23) and 
had significantly higher transcript levels in AD subjects compared to PSP (Table 3). The 
direction and effect size of disease association for myelination modules between these 
independent cohorts was remarkably similar (Tables 1 and 3). In contrast, none of the 3 
myelination CEM in the Replication Cohort under the Comprehensive Model showed 
disease association in the AD vs. PSP analysis (Table 3), unlike the corresponding analysis 
in the Discovery Cohort (Table 1).
To distinguish whether the higher levels of myelination networks in AD vs. PSP TCX are 
due to an upregulation in AD or more downregulation in PSP brains, we compared the 
elderly control brain tissue in the Replication Cohort against either AD or PSP TCX 
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transcriptome. Under the Simple Model, we identified two myelination CEM each in the AD
+control and PSP+control analyses. Both PSP+Control (Table 3, PSP+ConTCX5.CSRSsimple, 
PSP+ConTCX12.CSRSsimple) TCX CEM were significantly lower in PSP. Under the 
Comprehensive Model, there were 4 AD+control and 2 PSP+control myelination CEM. 
Interestingly all these modules showed lower myelination network levels in both 
neurodegenerative disease groups in comparison to controls, one of which achieved 
statistical significance (Table 3, AD+ConTCX7.CSRS).
Together with the results from the Discovery Cohort, these findings suggest that myelination 
networks are downregulated in both AD and PSP compared to controls, but are more 
downregulated in PSP. For the Replication Cohort, the network associations with PSP are 
more pronounced in the Simple Model, whereas those for AD are more pronounced in the 
Comprehensive Model. Nevertheless, levels of the oligodendrocyte marker OLIG2 are not 
significantly different between diagnostic groups (Supplementary Fig. 4C). Therefore 
downregulation of myelination networks in these diseases cannot be entirely explained by 
oligodendrocyte cell population changes (Supplementary Text).
3.4 Myelination co-expression modules harbor neurodegenerative disease risk genes with 
replicable differential expression
To investigate the genes from the myelination modules further, we focused on a subset that 
have the highest module membership (MM); in addition to genes that are implicated in the 
pathophysiology of AD[33, 34], PSP[35], or in myelin biology[36] (Supplementary Results, 
Table 4). We evaluated the AD vs. PSP differential expression of these individual transcripts 
in the Discovery and Replication Cohorts, under the Simple and Comprehensive Models. We 
also performed DGE analyses for all other pairwise diagnostic comparisons (Supplementary 
Table 34).
MM values close to 1 reflect high connectivity of the gene to the module[14]. The MM 
values of these genes were generally high (>0.70) and similar in all analyses (Table 4). 
Under the Simple Model, all 20 genes had higher levels in AD compared to PSP TCX in 
both cohorts, with remarkably consistent effect estimates. All 20 transcript associations were 
significant in the Discovery and 8 in the Replication Cohort, including disease implicated 
genes PSEN1, SLCO1A2 and CR1. Under the Comprehensive Model, in the Discovery 
Cohort, all 20 genes had higher TCX level estimates in AD subjects vs. PSP, 14 of which 
were statistically significant. In the Replication Cohort, none of the associations were 
retained under the Comprehensive Model, suggesting that cell-type adjustment may be 
accounting for a larger portion of the diagnostic differences for these genes in this cohort.
To determine whether the transcriptional changes observed in the TCX was also reflected in 
protein levels, we sought to validate these findings by performing western blot analyses in 
TCX samples (Supplementary Table 35, Supplementary Fig. 24). Given the limited dynamic 
range for quantitation of blots labeled with HRP-tagged antibodies, as in our study, these 
western blots should be considered as semi-quantitative. Despite significant variability, all 
myelin proteins had lower levels in PSP TCX (Supplementary Fig. 24. A–F) consistent with 
the transcript results, although these trends did not reach statistical significance, likely due to 
the relatively small sample size of this protein analysis cohort. All myelin proteins except 
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MOG and PLLP had lower level estimates in AD TCX (Supplementary Fig. 24. G–L), but 
not statistically significant, highlighting the need to evaluate much larger cohorts for protein 
validations.
Using proteome data from a larger cohort of 84 AD and 83 PSP TCX samples, obtained with 
Liquid Chromatography Coupled to Tandem Mass Spectrometry (LC-MS/MS) analysis, we 
identified significantly lower protein levels for myelin proteins MBP and CNP in PSP 
compared with AD TCX; and lower estimates that did not reach statistical significance for 
MOG, PLP1 and BIN1 (Supplementary Table.36). As expected, GFAP, APP and MAPT 
protein levels were lower in PSP compared to AD TCX.
We assessed myelination patterns, as well as microgliosis and astrogliosis in a subset of AD, 
PSP and control TCX samples (Supplementary Table 37, Supplementary Fig. 25). As 
expected, there is variability in the level of pathology. Given this and the small number of 
samples assessed, statistical differences in quantitative neuropathology cannot be detected. 
Nevertheless, the pattern of reduced myelination can be appreciated in select AD and PSP 
vs. control TCX samples. We evaluated immunocytochemical patterns for the myelin and 
oligodendrocyte proteins in rat primary oligodendrocyte-enriched cultures and demonstrated 
high cell type selectivity and regional specificity of selected antibodies for their cellular 
targets (Supplementary Table 38, Supplementary Fig.26–27, Supplementary_Text).
4. Discussion
In this study, we identified highly conserved myelination networks that are altered in both 
PSP and AD brains but to a greater extent in the former. This study is distinct from prior 
transcriptome studies in neurodegenerative diseases[3, 5, 6, 37] in several ways. We provide 
comparison of multiple neurodegenerative conditions, in addition to controls; use two 
independent cohorts; study two brain regions; use two different approaches for measuring 
gene expression; assess cell population variability; and perform protein validations 
(Supplementary Discussion). The underlying premise of our approach is that comparative 
analyses of different neurodegenerative diseases can uncover transcripts and molecular 
networks that are disease-specific as well as those that underlie shared aspects of disease 
pathology. To our knowledge, this is the first study, which has performed a systematic 
comparison of brain transcriptomes from AD vs. a primary tauopathy, PSP. Our conclusions 
are based on a collective dataset of 940 brain transcriptomes.
Our study yields insights into the role of myelination in the pathophysiology of two 
neurodegenerative diseases. To our knowledge oligodendrocyte/myelination pathways have 
not been studied comparatively in AD vs. PSP at a systems-biology level. There is evidence 
from neuropathology that oligodendrocyte/myelination dysfunction could contribute to both 
AD and PSP. Oligodendroglial tau deposits are a key aspect of PSP neuropathology[12]. 
Myelin loss was demonstrated in AD white matter (WM)[38], and focal intracortical 
demyelination associated with Aβ plaques was observed in AD gray matter (GM)[39]. 
Further, human brain myelination has distinct aspects that may predispose it to 
vulnerabilities resulting in neuropsychiatric illness[36, 40]. Myelination in humans an 
evolutionarily late event, which is distinguished from that of other species by its extent in 
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both gray and white matter (GM, WM) and by developmental myelination extending well 
into middle ages[36].
We find that brain gene expression networks enriched in oligodendrocyte transcripts 
involved in myelination are downregulated in PSP compared to AD. This downregulation is 
observed in two independent cohorts and is retained in the Discovery Cohort, even after 
adjusting for cell-specific markers (Comprehensive Model) to account for any cell-
population changes. The similarity in the findings in the Discovery Cohort under both the 
Simple and Comprehensive Models suggest that the transcriptional changes are unlikely to 
be solely due to cell-population changes. This is further corroborated by the fact that TCX, 
where these transcriptional changes are observed, is a region typically unaffected by PSP 
pathology[12]. Myelination networks are also downregulated in PSP TCX in comparison to 
controls, providing further support that these transcriptional changes are unlikely to be due 
to gross changes in pathology.
The depression of these findings under the Comprehensive Model in the Replication, but not 
the Discovery Cohort, may be multifactorial. First, the latter has >50% greater sample size. 
Second, RNAseq measures in the Replication Cohort may provide a more precise 
measurement of gene levels that may have led to better adjustment for cell-type changes or 
over-correction due to their stronger inter-correlation.
Importantly, there is downregulation of myelin proteins in PSP TCX in protein data from 
167 brain samples assessed by LC-MS/MS, as well as a smaller cohort evaluated by semi-
quantitative western blots analysis. Myelination patterns and cellular specificity of the 
antibodies used to assess myelination proteins are demonstrated by immunohistochemistry 
and immunocytochemistry in human brains and rat primary oligodendrocyte-enriched 
cultures. Thus, our transcriptome findings are also corroborated by protein data.
Our study paradigm allowed us to distinguish that myelination networks may also be 
downregulated in AD, but to a lesser extent than in PSP, rather than simply being 
upregulated in AD vs. PSP. This lesser alteration in AD TCX is intriguing, especially given 
that AD, unlike PSP, has significant pathology in TCX[9]. This finding further implies that 
the myelination network changes are unlikely to be a mere consequence of pathology. The 
enhanced vulnerability of myelination networks in PSP, in comparison to AD, leads to a 
number of compelling hypotheses. Both AD and PSP are characterized by aggregates of tau, 
which is a microtubule associated protein (MAP) and a constituent of both neurons and 
oligodendrocytes[13, 40]. Microtubules (MT) and tau are integral to oligodendroglial 
function and myelination, which are disrupted when tau is either overexpressed or 
downregulated. Hence, alteration of myelination networks in both AD and PSP is consistent 
with these data.
A key question is why this alteration is more enhanced in PSP in a brain region far less 
affected than in AD. One explanation may be the difference in the type of tau aggregate, 
with PSP harboring 4R-tau aggregates, composed of a tau isoform with 4 MT-binding 
domains, whereas AD has both 3R- and 4R-tau aggregates. In cultured oligodendrocytes, 
4R-tau becomes increased and 3R-tau decreased with development[40]. We can therefore 
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postulate that myelination pathways may be more vulnerable to 4R-tauopathies, such as PSP. 
Another reason may be the presence of genetic risk factors in PSP with a role in 
myelination. Indeed, variants in/near MOBP are implicated in risk of PSP[35], and 
CBD[41], another 4R-tauopathy. MOBP encodes the CNS-expressed myelin-associated 
oligodendrocytic basic protein, which is a member of the myelination networks identified 
herein.
Another finding from our study is the remarkable conservation of brain transcriptional 
networks that are independently constructed in two brain regions, TCX and CER. This 
finding is consistent with the prior observations in healthy control brains[42], and suggest 
that the broad architecture of the brain transcriptional networks is unlikely to be driven by 
cell population differences in disease-affected vs. –unaffected tissue. Additionally, although 
we focused on myelination networks in this study, we identified modules enriched in 
astrocytic, microglial and neuronal transcripts, which show consistencies with prior 
transcriptome studies[6, 37, 43]. The detailed findings from our analyses that we present 
here, as well as the accessibility of our large-scale data[16] should establish this study as a 
highly useful resource.
In summary, our study identifies downregulation of myelination networks as a potential 
pathophysiologic component of both PSP and AD. Our findings are based on postmortem 
brain tissue which reflects a “snapshot” of gene expression networks for end-stage disease. 
Nevertheless, this work can be instrumental in launching future biomarker or therapeutic 
discovery efforts. Neuroimaging studies in living patients support white matter[44, 45] and 
specifically myelin alterations[46] in preclinical AD. Key molecules within myelination 
networks identified in our study can serve to develop novel molecular imaging tools for 
tracking myelin neuropathology in longitudinal cohorts followed for incident AD and other 
neurodegenerative diseases. Such cohorts should also enable detection of longitudinal 
changes in gene and protein expression levels for these molecules, which can help establish 
their temporal relationship with cognitive and other clinical outcomes. These future studies 
can provide fundamental new insight into the role of myelin dysregulation in the cascade of 
pathophysiological processes in AD[47] and other neurodegenerative conditions. 
Additionally, the specific expression network alterations uncovered in our study can be 
tested in model systems for their potential as therapeutic targets. There are known 
interactions between oligodendrocytes and the other CNS cell-types; including inflammatory 
and astrocytic activation in myelin breakdown and remyelination[36]. We find that 
established and candidate AD genes[34], such as PSEN1, BIN1 and CR1, reside in 
myelination modules. Given these and the effects of both tau[12, 40] and Aβ[38, 39] on 
myelination, we posit that myelin may indeed be the “glue” that holds together key 
biological functions in the adult brain, the disruption of which results in neuropsychiatric 
conditions such as AD and PSP.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Aβ Amyloid β
AD Alzheimer’s disease
AD+PSPTCX AD vs. PSP temporal cortex analyses
AD+PSPCER AD vs. PSP cerebellum analyses
AD+ConTCX AD vs. Control temporal cortex analyses
AD+ConCER AD vs. Control cerebellum analyses
ALS Amyotrophic lateral sclerosis
CBD Corticobasal degeneration
CEM Co-expression modules
CER Cerebellum
CNS Central nervous system
DE Differential expression/differentially expressed
DGE Differential gene expression
eGWAS Expression genome-wide association study(ies)
eQTL Expression quantitative trait locus/loci.
FDR False discovery rate
FPKM fragments per kilobase per million
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FTLD Frontotemporal lobar degeneration
GO Gene Ontology
GWAS Genome-wide association study(ies)
IGAP International Genetics of AD Project
LBD Lewy body disease
MM Module membership
MS Multiple sclerosis
MSA Multiple system atrophy
nAD CNS diseases (non-AD, includes PSP and nTau)
nTau CNS diseases without primary tau or AD pathology (non-
Tau)
PD Parkinson’s disease
PSP Progressive supranuclear palsy
PSP+ConTCX PSP vs. Control temporal cortex analyses
PSP+ConCER PSP vs. Control cerebellum analyses
QC Quality control
RNAseq RNA sequencing
TCX Temporal cortex
VaD Vascular dementia
WGCNA Weighted gene co-expression network analysis
WG-DASL Whole genome cDNA-mediated Annealing, Selection, 
Extension, and Ligation
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Highlights
• Brain myelination transcriptional networks are downregulated in PSP and 
AD.
• Myelination networks are higher in AD vs. PSP but lower compared to 
controls.
• Network structures, but not expression changes, are preserved between TCX 
and CER.
• Brain cell type changes can influence and need adjustment in transcriptome 
studies.
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RESEARCH IN CONTEXT
Systemic review
Reviewing the literature for gene expression profiling publications of neuro-
proteinopathies, showed that most studies are limited to small cohorts and individual 
gene transcript rather than systems-level analysis. Further, most studies assess one 
disease group against controls, rather than comparative transcriptome analyses of 
different diseases.
Interpretation
Comparative transcriptome analyses in Alzheimer’s disease (AD) and other 
neurodegenerative proteinopathies can uncover both shared and distinct disease 
pathways. Our analysis of 940 brain transcriptomes including patients with AD, 
progressive supranuclear palsy (PSP) and controls identified down-regulation of 
myelination networks in both AD and PSP, but more pronounced in the latter.
Future directions
Future studies should investigate in ante-mortem cohorts, longitudinal changes in 
myelination network molecules to determine their role in the pathophysiological 
processes in AD and other neurodegenerative diseases with a goal to establish them as 
novel biomarkers. The myelination network molecules should be tested in model systems 
for their potential as therapeutic targets.
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Fig. 1. Volcano plots of fold change vs. significance for differential gene expression (DGE) in the 
temporal cortex (TCX)
Results are shown for the primary analysis of AD vs. PSP TCX DGE in the Discovery 
Cohort, under the Simple (A0–A9) and Comprehensive (B0–B11) models. Each circle 
represents a transcript, which are colored differently according to the CEM they pertain to. 
Transcripts with strong module membership (MM) values≥0.7 are shown as filled circles; or 
empty circles if MM<0.7. Results are shown for all transcripts analyzed (A0, B0) and also 
separately for those CEM with consistent brain cell-enrichment across both models. DGE 
results that are significant at q≤0.05 or q≤0.01 are shown above the green and red dotted 
lines, respectively.
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Fig. 2. Oligodendrocyte networks in the Discovery and Replication Cohorts with disease 
association
Temporal cortex (TCX) oligodendrocyte-specific gene enriched networks in the Discovery 
Cohort under the Simple (A, B) and Comprehensive Models (C, D); and in the Replication 
Cohort under the Simple Model are shown for the primary AD vs. PSP analysis. These 
CEMs have significantly different levels between AD and PSP. None of the corresponding 
modules in the Replication Cohort under the Comprehensive Model were significantly 
associated with disease. The circles or squares represent the nodes for the genes within the 
CEM. For each module, the top 150 connections according to TOM weight are shown for 
genes with a MM > 0.7. The size of a node correlates with the number of connections for 
that node with others within the network. Gene transcripts that are enriched within 
oligodendrocytes are shown in orange. Transcripts with significant differential expression at 
q<0.05 are shown as a square. Thickness of the connection lines is determined by the weight 
of the connection.
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